Pacific Edge Announces Key Activities at AUA 2026

Pacific Edge today announces its key activities at the American Urological Association’s (AUA) Annual Meeting, May 15-18 in Washington DC.

The AUA Annual Meeting, the largest and most influential event in the US and global urological calendar, provides an important opportunity to present and discuss new clinical evidence. One key study to be presented as a poster – A Randomized Multicenter Crossover Study to Evaluate Patient Preference and Satisfaction With Urine-Based Molecular Testing vs Cystoscopy for Surveillance of Non-Muscle-Invasive Bladder Cancer – clearly demonstrates that patients prefer non-invasive urine-based testing over cystoscopy (>70%). The study was led by Mark D. Tyson, MD, MPH from the Department of Urology, Mayo Clinic, Phoenix, AZ and provides new clinical insights that strengthen the strategic and commercial positioning of Cxbladder Monitor as a complement or alternative to cystoscopy in bladder cancer surveillance.

On Sunday, 17 May, Pacific Edge will exhibit at the Annual Meeting of the Urological Society of American Veterans (USAV). This will provide the team with an opportunity to highlight the recent publication of the DRIVE study¹. The DRIVE Study (Detection and Risk Stratification In Veterans Presenting with Hematuria) evaluated the prognostic performance of Cxbladder Triage Plus² compared to cystoscopy. It showed that Triage Plus demonstrated similarly high-performance characteristics in the veterans’ population when compared with its proof-of-concept study³.

The authors of the study concluded: “Cxbladder Triage Plus demonstrated clinical validity in this VA population with gross hematuria or microhematuria, with high sensitivity and specificity. These findings indicate that Triage Plus may be safely used to rule out or detect [urothelial cancer] in patients with hematuria.”

Session details:

• 2026 USAV Annual Meeting
• 7:30am – 12pm EST
• Marriot Marquis Washington DC, Salons 1-5, Meeting Level 2

To anchor its presence at the event, Pacific Edge will be hosting a booth in the main hall, where the Team will be highlighting:

• The latest improvements in the CxConnect Customer Portal, a platform designed to streamline the digital customer experience, simplifying Cxbladder ordering and reporting
• The new peer-reviewed evidence – specifically, the DRIVE Study that showed the clinical validation of Triage Plus and the Kaiser Permanente Study which was the largest real-world evidence study of a urine-based biomarker for hematuria evaluation with Triage
• Real world commercial success stories from implementing clinical pathways according to the AUA/SUFU Microhematuria Guideline⁴ for Cxbladder Triage
• The summary of expert opinions from the Contractor Advisory Committee (CAC) held on 19 February, including the unmet clinical need for urine-based biomarkers to address all risk categories of microhematuria; address gross hematuria; help deliver healthcare equity for patients in rural areas, and in underserved patient groups like women whose hematuria is often dismissed as a symptom of a urinary tract infection.

Pacific Edge CEO Peter Meintjes said. “AUA provides a unique opportunity to connect with urological teams from across the country. We look forward to discussing the results of the Mayo Clinic study, which clearly demonstrates that patients value the comfort, convenience, and non‑invasive nature of Cxbladder Monitor and that they can use the test while maintaining confidence in their cancer surveillance regime.

“With Cxbladder Triage a focus for us, the weight of evidence and clinical endorsement in support of Cxbladder testing for hematuria evaluation – including a positive panel meeting in February – will provide a strong base for discussion.”

Further information on AUA 2026 can be found here. We look forward to speaking with all of those who are planning to attend and invite you to visit us at booth #3707. If you're attending and have any questions leading up to the event, please contact your Cxbladder representative or email us at cs-pedusa@pacificedgedx.com.

¹ Savage et al. (2025) Diagnostic Performance of Cxbladder Triage Plus for the Identification and Stratification of Patients at Risk for Urothelial Carcinoma: The Multicenter, Prospective, Observational DRIVE Study.Urologic Oncology, S1078-1439(25)00405-3
² Cxbladder Triage Plus is a next generation Cxbladder test that employs a novel combination of mRNA and DNA biomarkers to extend best in class performance in the risk stratification in patients presenting with hematuria. The US launch of Triage Plus is forthcoming.
³ Lotan, Y., Raman, J. D., Konety, B., Daneshmand, S., Schroeck, F., Shariat, S. F., … Eng, M. (2023). Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification. Journal of Urology, 209(4), 762–772. https://doi.org/10.1097/JU.0000000000003126
⁴ Barocas DA, Lotan Y, Matulewicz RS, Raman JD, Westerman ME, Kirkby E, Pak L, Souter L. (2025) Updates to Microhematuria: AUA/SUFU Guideline. J Urol. doi: 10.1097/JU.0000000000004490.